HER2-Positive Early Stage Breast Cancer Active Not Recruiting Phase 3 Trials for Pertuzumab (DB06366)

Also known as: HER2-Positive Early Breast Cancer / HER2-positive early-stage breast cancer / Early Stage HER2+ Breast Cancer / HER2 Positive Early Breast Cancer

IndicationStatusPhase
DBCOND0063722 (HER2-Positive Early Stage Breast Cancer)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05113251Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerTreatment
NCT04024462A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerTreatment